We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+34.57%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$712M
AUM Growth
+$90.4M
Cap. Flow
+$220K
Cap. Flow %
0.03%
Top 10 Hldgs %
33.84%
Holding
126
New
27
Increased
25
Reduced
33
Closed
22

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$10.6M
2
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
3
HELP
Cybin Inc
HELP
+$9.73M
4
S icon
SentinelOne
S
+$8.81M
5
JSPR icon
Jasper Therapeutics
JSPR
+$7.71M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$15.3M
2
ATXS
Astria Therapeutics
ATXS
+$12.9M
3
TSEM icon
Tower Semiconductor
TSEM
+$10.9M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.61M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 65.19%
2 Technology 15.63%
3 Communication Services 2.68%
4 Consumer Discretionary 2.45%
5 Utilities 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEN icon
76
Compugen
CGEN
$222M
$1.98M 0.28%
769,239
– –
NTR icon
77
Nutrien
NTR
$33.2B
$1.94M 0.27%
+35,730
New +$1.86M
SEDG icon
78
CALL
SolarEdge
SEDG
$2.51B
$1.9M 0.27%
26,800
– –
KZR
79
DELISTED
Kezar Life Sciences
KZR
$1.85M 0.26%
205,168
– –
ACAD icon
80
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
$1.85M 0.26%
+100,000
New +$2.48M
APRE icon
81
Aprea Therapeutics
APRE
$7.68M
$1.81M 0.25%
+270,000
New +$1.68M
ALPN
82
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.78M 0.25%
44,841
-190,000
-81% -$5.61M
FIVN icon
83
FIVE9
FIVN
$2.11B
$1.71M 0.24%
27,500
+12,500
+83% +$868K
CRGX
84
DELISTED
CARGO Therapeutics
CRGX
$1.67M 0.24%
75,000
– –
ATXS
85
DELISTED
Astria Therapeutics
ATXS
$1.59M 0.22%
112,842
-1,038,303
-90% -$12.9M
IRON icon
86
CALL
Disc Medicine
IRON
$2.96B
$1.56M 0.22%
+25,000
New +$1.62M
BBIO icon
87
CALL
BridgeBio Pharma
BBIO
$15.7B
$1.55M 0.22%
+50,000
New +$1.7M
PRME icon
88
Prime Medicine
PRME
$527M
$1.44M 0.2%
205,242
+131,262
+177% +$995K
UPWK icon
89
Upwork
UPWK
$1.13B
$1.43M 0.2%
117,000
-135,784
-54% -$1.85M
CRBP icon
90
Corbus Pharmaceuticals
CRBP
$166M
$1.37M 0.19%
+35,000
New +$863K
AVGO icon
91
Broadcom
AVGO
$1.85T
$1.33M 0.19%
10,010
-7,990
-44% -$990K
GERN icon
92
Geron
GERN
$828M
$1.27M 0.18%
+384,356
New +$861K
LVTX
93
DELISTED
LAVA Therapeutics
LVTX
$1.22M 0.17%
+367,582
New +$809K
GOSS icon
94
Gossamer Bio
GOSS
$82.9M
$1.21M 0.17%
1,027,134
-310,956
-23% -$342K
VRNS icon
95
Varonis Systems
VRNS
$4.59B
$943K 0.13%
+20,000
New +$952K
INSM icon
96
CALL
Insmed
INSM
$21.4B
$762K 0.11%
+28,100
New +$786K
AMLX icon
97
Amylyx Pharmaceuticals
AMLX
$2.26B
$759K 0.11%
267,250
+83,600
+46% +$1.09M
ICL icon
98
ICL Group
ICL
$6.53B
$702K 0.1%
130,475
-289,525
-69% -$1.42M
AMLX icon
99
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$682K 0.1%
240,000
+140,000
+140% +$1.83M
RNAC icon
100
Cartesian Therapeutics
RNAC
$229M
$489K 0.07%
836
-24,235
-97% -$514K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sphera Funds Management held 126 positions worth $712M, up 15% from $621M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management's Q1 2024 filing shows 27 new, 25 increased, 33 reduced and 22 closed positions. Its largest new stake was Cybin Inc: 673,195 shares worth $10.6M. The largest sale was Nova, an estimated $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2024 buy was Cybin Inc: 673,195 shares worth $10.6M.
  • Sphera Funds Management added most to Perspective Therapeutics in Q1 2024, an estimated $10.6M increase.
  • Sphera Funds Management's biggest Q1 2024 reduction was Nova, cutting an estimated $15.3M.
  • Sphera Funds Management fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $712M portfolio in Q1 2024.
  • Sphera Funds Management opened 27 new positions and closed 22 in Q1 2024.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $712M.

Based on Sphera Funds Management's 13F filing for Q1 2024, filed 15 May 2024.